期刊文献+

Gastrointestinal cancers in the era of theranostics: Updates and future perspectives

Gastrointestinal cancers in the era of theranostics: Updates and future perspectives
下载PDF
导出
摘要 Theranostics are one of the practical aspects of personalized medicine.This concept was designed to describe a material combining diagnosis,treatment and follow up of a disease.It evolved and included molecular targeting and nanotechnologies that incorporate both diagnosis and therapeutics.In this editorial,we are presenting briefly the concept and evolution of theranostics,highlighting many applications of theranostics in daily practice and discussing future perspectives and aspects of this model in gastrointestincal cancers. Theranostics are one of the practical aspects of personalized medicine.This concept was designed to describe a material combining diagnosis,treatment and follow up of a disease.It evolved and included molecular targeting and nanotechnologies that incorporate both diagnosis and therapeutics.In this editorial,we are presenting briefly the concept and evolution of theranostics,highlighting many applications of theranostics in daily practice and discussing future perspectives and aspects of this model in gastrointestincal cancers.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第28期8473-8477,共5页 世界胃肠病学杂志(英文版)
关键词 THERANOSTICS GASTROINTESTINAL cancer Nanoparticles Nanotheranostics MOLECULAR TARGETING Theranostics Gastrointestinal cancer Nanoparticles Nanotheranostics Molecular targeting
  • 相关文献

参考文献34

  • 1Hajdu SI. A note from history: landmarks in history of cancer, part1. Cancer 2011; 117: 1097-1102 [PMID: 20960499 DOI: 10.1002/cncr.25553].
  • 2Love RR, Philips J. Oophorectomy for breast cancer: historyrevisited. J Natl Cancer Inst 2002; 94: 1433-1434 [PMID: 12359852DOI: 10.1093/jnci/94.19].
  • 3Sumer B, Gao J. Theranostic nanomedicine for cancer.Nanomedicine (Lond) 2008; 3: 137-140 [PMID: 18373419 DOI:10.2217/17435889.3.2.137].
  • 4Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, GuarneriV, D'Amico R. Trastuzumab containing regimens for early breastcancer. Cochrane Database Syst Rev 2012; 4: CD006243 [PMID:22513938 DOI: 10.1002/14651858.CD006243.pub2].
  • 5Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, MojaL, D'Amico R. Trastuzumab-containing regimens for metastaticbreast cancer. Cochrane Database Syst Rev 2014; 6: CD006242[PMID: 24919460 DOI: 10.1002/14651858.CD006242.pub2].
  • 6Hao M, Song F, Du X, Wang G, Yang Y, Chen K, Yang J.Advances in targeted therapy for unresectable melanoma: newdrugs and combinations. Cancer Lett 2015; 359: 1-8 [PMID:25578781 DOI: 10.1016/j.canlet.2014.12.050].
  • 7Hendifar A, Tan CR, Annamalai A, Tuli R. Biomarker-drivenEGFR therapy improves outcomes in patients with metastaticcolorectal cancer. Expert Rev Anticancer Ther 2014; 14: 1051-1061[PMID: 24898788 DOI: 10.1586/14737140.2014.922881].
  • 8Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, SalgiaR, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, DoebeleRC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, TyeLM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl JMed 2014; 371: 1963-1971 [PMID: 25264305 DOI: 10.1056/NEJMoa1406766].
  • 9Stinchcombe TE. Recent advances in the treatment of non-smallcell and small cell lung cancer. F1000Prime Rep 2014; 6: 117[PMID: 25580271 DOI: 10.12703/P6-117].
  • 10Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, BealsB, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P.Increased antitumor activity, intratumor paclitaxel concentrations,and endothelial cell transport of cremophor-free, albumin-boundpaclitaxel, ABI-007, compared with cremophor-based paclitax- el.Clin Cancer Res 2006; 12: 1317-1324 [DOI: 10.1158/1078-0432.CCR-05-1634].

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部